Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC)

Document Type

Conference Proceeding

Publication Date

2-27-2024

Publication Title

Journal of Clinical Oncology

Abstract

2024 ASCO Gastrointestinal Cancers Symposium

First Page

666

Volume

42

Comments

Abstract Number: 666

This document is currently not available here.

Share

COinS